FNCHQ — Finch Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $16.62m
- $0.58m
- $0.11m
Brief: Finch Therapeutics Provides An Update On Its Phase 3 Trial Of CP101 In Recurrent C. Difficile Infection
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:27 PM
Brief: Finch Therapeutics Group Preliminarily Estimates That Its Cash And Cash Equivalents As Of Dec 31, 2021 Was About $133.5 Mln
Brief: Finch Therapeutics Further Strengthens Patent Portfolio With Two New U.S. Patents Granted For Fin-211, An Investigational Microbiome Therapeutic In Development For Autism Spectrum Disorder
Brief: Finch Therapeutics Reports Third Quarter 2021 Financial Results
Brief: Finch Therapeutics Announces Start Of Enrollment In PRISM4 Phase 3 Trial
Brief: Finch Therapeutics Presents Positive Data From Mid-Stage Trial Of CP101 For Recurrent C. Difficile At American College Of Gastroenterology Annual Scientific Meeting
Brief: Finch Therapeutics Announces The Appointment Of Marc Blaustein As Chief Operating Officer
Finch Therapeutics Group Inc reports results for the quarter ended in June - Earnings Summary
Brief: Finch Therapeutics Group Inc Announces Takeda To Accelerate Leadership Role In Fin-524 Ulcerative Colitis Development Program
Brief: Finch Therapeutics Reports Second Quarter 2021 Financial Results And Provides Business Update
Brief: Finch Therapeutics Added To Russell 2000 And Russell 3000 Indexes
NASDAQ RESUMED AT 09:41 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:36 AM
Finch Therapeutics Group Inc reports results for the quarter ended in March - Earnings Summary
U.S. RESEARCH ROUNDUP-IRhythm Technologies, Northwestern, Supernus Pharmaceuticals
Live Markets: IPO March madness returns